Dermoscopy in the era of dermato-oncology: from bed to bench side and retour.

abstract：:According to computed tomography image analysis, skeletal muscle (SM) and adipose tissue areas vary widely in patients with the same body mass index or the same body surface area. Body composition variables such as SM mass, SM density and subcutaneous and visceral adipose tissue have shown value as potential independe...

journal_title：Expert review of anticancer therapy

authors： Antoun S,Lanoy E,Albiges-Sauvin L,Escudier B

更新日期：2014-03-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) patients with metastases limited in site and number, termed oligometastases, may represent a unique subpopulation of advanced NSCLC with improved prognosis. The optimal management of these patients remains unclear with the treatment approach currently undergoing a paradigm shift. The...

journal_title：Expert review of anticancer therapy

authors： Bergsma DP,Salama JK,Singh DP,Chmura SJ,Milano MT

更新日期：2015-01-01 00:00:00

abstract：:Ductal carcinoma in situ is a premalignant disease of the breast with a rapidly rising incidence. For women with localized ductal carcinoma in situ, randomized trials have shown that radiation therapy following conservative surgery lowers the relative risk of progression to invasive disease by 60%. Therefore, followin...

journal_title：Expert review of anticancer therapy

authors： Smith BD,Smith GL,Buchholz TA

更新日期：2008-03-01 00:00:00

abstract：:Oncolytic viruses are novel anticancer agents, currently under investigation in Phase I-III clinical trials. Until recently, most studies have focused on the direct antitumor properties of these viruses, although there is now an increasing body of evidence that the host immune response may be critical to the efficacy ...

journal_title：Expert review of anticancer therapy

authors： Prestwich RJ,Harrington KJ,Pandha HS,Vile RG,Melcher AA,Errington F

更新日期：2008-10-01 00:00:00

abstract：:Bladder cancer is a significant cause of morbidity and mortality. Promising results with organ preservation strategies using multimodality treatment over the last decade offers an option for bladder preservation in a significant proportion of patients who currently undergo cystectomy. The primary goal of the bladder-s...

journal_title：Expert review of anticancer therapy

authors： Hussain SA,James ND

更新日期：2002-12-01 00:00:00

abstract：INTRODUCTION:A systematic review was performed to explore the health-related quality of life (HRQoL) outcomes among cancer patients receiving PD-(L)1 inhibitors compared to those receiving traditional cytotoxic therapy. Areas covered: Citations from PubMed and the American Society of Clinical Oncology meeting library w...

journal_title：Expert review of anticancer therapy

authors： Abdel-Rahman O,Oweira H,Giryes A

更新日期：2018-12-01 00:00:00

abstract：:In breast cancer, RANK ligand (RANKL) appears to play an important role in the process of chemotaxis between circulating tumor cells and the bone microenvironment, which enables RANK-expressing breast cancer cells to migrate into the bone. Mounting clinical evidence has further demonstrated that the anti-RANKL monoclo...

journal_title：Expert review of anticancer therapy

authors： Azim H,Azim HA Jr

更新日期：2013-02-01 00:00:00

abstract：:Tyrosine kinase inhibitors have revolutionized the treatment of metastatic renal cell carcinoma (RCC). Drugs such as sorafenib, sunitinib and pazopanib act on the VEGF receptor pathway, but they can also inhibit other kinases, resulting in off-target toxicities. Tivozanib was developed due to its potency and selectivi...

journal_title：Expert review of anticancer therapy

authors： Wong HH,Eisen T

更新日期：2013-06-01 00:00:00

abstract：INTRODUCTION:To date, all efforts to fight gastrointestinal cancer, regardless of its origin and entity, have resulted in complex therapeutic regimens involving a combination of systemic therapy, radiation therapy and surgery. It is generally accepted across all disciplines that not one, but the combination and the pro...

journal_title：Expert review of anticancer therapy

authors： Neumann PA,Berlet MW,Friess H

更新日期：2021-01-08 00:00:00

abstract：:The purpose of this article is to outline the current approach to patients affected by metastasis to the long bones and to present a clinical and surgical algorithm available for clinicians and for future research. A modern approach to patients affected by long bone metastasis in fact requires a multidisciplinary cont...

journal_title：Expert review of anticancer therapy

authors： Capanna R,Piccioli A,Di Martino A,Daolio PA,Ippolito V,Maccauro G,Piana R,Ruggieri P,Gasbarrini A,Spinelli MS,Campanacci DA,Italian Orthopaedic Society Bone Metastasis Study Group.

更新日期：2014-10-01 00:00:00

abstract：:Medical therapy represents an alternative treatment approach that can be considered for some forms of non-melanoma skin cancer (NMSC). In selected cases, topical treatments are preferable to invasive procedures, especially in the case of multifocal lesions, unclear lesion edges, risk of keloids, surgical risk factors ...

journal_title：Expert review of anticancer therapy

authors： Micali G,Lacarrubba F,Bhatt K,Nasca MR

更新日期：2013-12-01 00:00:00

abstract：:Stereotactic body radiation therapy (SBRT) involves delivery of image-guided, ablative radiation doses to planning treatment volume(s) using sophisticated dosimetric planning and target localization. Early on, clinical investigators pursued SBRT for the treatment of early stage non-small-cell lung cancer, lung and liv...

journal_title：Expert review of anticancer therapy

authors： Mayr NA,Huang Z,Sohn JW,Lo SS,Teh BS,Lu JJ,Grecula JC,Kunos C

更新日期：2011-07-01 00:00:00

abstract：INTRODUCTION:Intrahepatic cholangiocarcinoma (ICC) is a highly malignant neoplasm. The incidence of ICC has been increasing world-wide over the past several decades. Areas covered: The pathogenesis of ICC is a complex process involving the alteration of specific genes and epigenetic changes. This review summarizes the ...

journal_title：Expert review of anticancer therapy

authors： Huang SB,Zheng CX

更新日期：2017-01-01 00:00:00

abstract：INTRODUCTION:In the last decade tyrosine kinase inhibitors (TKIs) have been employed for a wide range of hematological and solid tumors and today they represent a valid therapeutic option for different neoplasms. Among them, both sorafenib and lenvatinib were approved for the treatment of radioactive iodine (RAI) refra...

journal_title：Expert review of anticancer therapy

authors： Felicetti F,Nervo A,Piovesan A,Berardelli R,Marchisio F,Gallo M,Arvat E

更新日期：2017-12-01 00:00:00

abstract：:The Second European Lung Cancer Conference was held in Geneva, Switzerland from 28 April to 1 May 2010, under the cosponsorship of the International Association for the Study of Lung Cancer and the European Society for Medical Oncology. The main topics included: tobacco control, which represents a crucial challenge fo...

journal_title：Expert review of anticancer therapy

authors： Girard N,Mornex F

更新日期：2010-07-01 00:00:00

abstract：INTRODUCTION:The therapeutic armamentarium for advanced soft tissue sarcoma (STS) has increased over the last few years. Doxorubicin monotherapy or in combination is now the established first line treatment. Beyond first line treatment, no standard therapy has been established. Novel drugs have reached the late-clinica...

journal_title：Expert review of anticancer therapy

authors： Skafida E,Kokkali S,Nikolaou M,Digklia A

更新日期：2017-06-01 00:00:00

abstract：:In the new era of 'precision' cancer medicine, new drug development has shifted from cytotoxic chemotherapy to molecularly targeted agents. Eribulin mesylate, a microtubule-destabilizing agent, is the only 'classical' cytotoxic agent approved for the treatment of breast cancer in the last 7 years. This synthetic analo...

journal_title：Expert review of anticancer therapy

authors： Polastro L,Aftimos PG,Awada A

更新日期：2014-06-01 00:00:00

abstract：:Intensity-modulated radiation therapy (IMRT) represents a powerful advance in the planning and delivery of radiation therapy owing to its ability to deliver highly conformal treatment doses while sparing normal tissues. Dosimetric studies have shown the feasibility and theoretical benefit of treating with IMRT over 3D...

journal_title：Expert review of anticancer therapy

authors： Bockbrader M,Kim E

更新日期：2009-05-01 00:00:00

abstract：:The prospects for the treatment of metastatic melanoma are improving. Whereas previous scientific meetings dedicated to the treatment of metastatic melanoma patients were overshadowed by our inability to improve overall survival or lengthen the time to progression, the results presented at the most recent meetings are...

journal_title：Expert review of anticancer therapy

authors： van Kempen LC

更新日期：2011-06-01 00:00:00

abstract：:Background: This evaluation emphasizes the main points of the original article 'Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies' by Sprenger et al. and provides further justification for the use of an alternative approach in the design...

journal_title：Expert review of anticancer therapy

authors： Roussos Torres ET,Epstein AL

更新日期：2021-01-19 00:00:00

abstract：:Introduction: Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumour, and its outcome is strongly conditioned by the rapid onset of resistance to conventional chemotherapeutics. First-line treatment with a combination of platinum agents and topoisomerase inhibitors has been the standard of care for...

journal_title：Expert review of anticancer therapy

authors： Van Den Borg R,Leonetti A,Tiseo M,Giovannetti E,Peters GJ

更新日期：2019-06-01 00:00:00

abstract：INTRODUCTION:The success of the immune checkpoint inhibitors in melanoma has reinvigorated the field of immunotherapy. Immune checkpoint inhibitors are now the standard of care in multiple cancer types including lung cancer, head and neck cancer, urothelial cancer and renal cell cancer. The field of immunotherapy is cu...

journal_title：Expert review of anticancer therapy

authors： O'reilly A,Larkin J

更新日期：2017-07-01 00:00:00

abstract：:Patients with unilateral breast cancer are at increased risk of developing a second cancer in the contralateral breast. Some women choose contralateral prophylactic mastectomy (CPM) to prevent cancer in the contralateral breast. Several studies have demonstrated that CPM significantly decreases the occurrence of contr...

journal_title：Expert review of anticancer therapy

authors： Tuttle T,Habermann E,Abraham A,Emory T,Virnig B

更新日期：2007-08-01 00:00:00

abstract：INTRODUCTION:About 50% of all patients with advanced testicular cancer demonstrate residual retroperitoneal or extraretroperitoneal masses. About two thirds of the masses harbour necrosis/fibrosis only whereas as about 10% and 40% harbour vital cancer or teratoma. Appropriate therapy will result in a high cure rate if ...

journal_title：Expert review of anticancer therapy

authors： Heidenreich A,Paffenholz P,Nestler T,Pfister D

更新日期：2019-04-01 00:00:00

abstract：INTRODUCTION:Endometrial cancer is the most common gynecologic malignancy in the developed world, and its incidence is increasing. Mortality from this cancer has not improved in recent decades and is primarily driven by high-grade carcinomas that are more likely to present at an advanced stage and ultimately are more l...

journal_title：Expert review of anticancer therapy

authors： Connor EV,Rose PG

更新日期：2018-09-01 00:00:00

abstract：:Kaposi sarcoma is the most common cancer among HIV-infected individuals and one of the most common cancers in sub-Saharan Africa. Kaposi sarcoma lesions are highly vascularized, and comprised of spindle-shaped tumor cells. Kaposi sarcoma herpesvirus is etiologically linked to Kaposi sarcoma development and encodes gen...

journal_title：Expert review of anticancer therapy

authors： Hansen A,Boshoff C,Lagos D

更新日期：2007-02-01 00:00:00

abstract：INTRODUCTION:In the recent years, melanoma patients' outcome and survival improved, mainly because of systemic treatment improvement with targeted therapy and checkpoint blockade. Targeted therapy with BRAF and MEK inhibitors was approved to treat patients with unresectable or metastatic melanoma, harboring BRAF V600 m...

journal_title：Expert review of anticancer therapy

authors： Amaral T,Nouri N,Garbe C

更新日期：2016-07-01 00:00:00

abstract：:The year 2006 will mark a turning point in the daily management of patients with metastatic renal cell carcinoma. The impact of immunotherapy with interferon-alpha or interleukin-2 has been shown to be restricted to a minority of patients. The growing understanding of molecular mechanisms involved in the pathogenesis ...

journal_title：Expert review of anticancer therapy

authors： Pouessel D,Culine S

更新日期：2006-12-01 00:00:00

abstract：:Before the advent of rationally designed targeted antineoplastic therapies, cladribine was identified as a lymphocyte-specific cytotoxic agent. Cladribine is a purine nucleoside analogue that is resistant to cellular catabolism. Through diverse mechanisms, cladribine is equally toxic to dividing and nondividing cells,...

journal_title：Expert review of anticancer therapy

authors： Sigal DS,Saven A

更新日期：2008-04-01 00:00:00

abstract：INTRODUCTION:The aim of this paper was to perform a narrative review of the literature on the available approaches in the treatment of two emerging subpopulations of metastatic renal cell carcinoma (mRCC) patients: the oligometastatic disease (less than 5 metastasis) and the oligoprogressive disease, defined as worseni...

journal_title：Expert review of anticancer therapy

authors： Donini M,Buti S,Massari F,Mollica V,Rizzo A,Montironi R,Bersanelli M,Santoni M

更新日期：2020-06-01 00:00:00